reproxalap

Reproxalap is a first-in-class small molecule drug candidate developed for the treatment of dry eye disease and allergic conjunctivitis. It acts as a modulator and inhibitor of reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory diseases. By inhibiting RASP, reproxalap reduces ocular inflammation, diminishes tear production issues, redness, and changes in tear lipid composition associated with dry eye disease. The drug has also been investigated for noninfectious anterior uveitis and Sjögren-Larsson syndrome, where it holds orphan drug status. Reproxalap works by rapidly binding to RASP such as malondialdehyde (MDA) and 4-hydroxy-2-nonenal (HNE), thereby preventing their pro-inflammatory effects mediated through pathways like NF-kB translocation, inflammasome activation, and scavenger receptor A binding[1][2][3][4][5][6][8].

Other names

reproxalapADX-102ADX102ADX 102NS-2NS2NS 2